Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Am Surg ; : 31348241248687, 2024 Apr 17.
Article in English | MEDLINE | ID: mdl-38631332

ABSTRACT

BACKGROUND: Underrepresented minority groups (URMs) in surgery are not significantly increasing despite evidence suggesting that diversity in health care providers leads to excellent patient outcomes and care. Efforts to increase URM representation in surgical residency programs are essential for addressing disparities and improving health care delivery. METHODS: This retrospective study outlines a three-phase strategy implemented at a large academic-affiliated hospital to increase URM representation in its general surgery residency program. The strategy encompassed interview selection with a holistic review and implicit bias training for interviewers, modification of the interview scoring rubric, and post-interview recruitment efforts, including a virtual second look event for URM applicants. RESULTS: Following the implementation of these strategies, the URM match rate improved from 0 to 33.3% in the first year and was sustained at 33.3% in the subsequent year. Consequently, the representation of URMs in the residency program rose from 6.7% before our intervention to 13.3% afterwards. DISCUSSION: This structured approach successfully increased URM representation in a surgical residency program, affirming the success of targeted recruitment strategies. By promoting a diverse and inclusive environment, the program better reflects the community it serves, with aims at improved patient care and patient satisfaction.

2.
Trauma Surg Acute Care Open ; 7(1): e000925, 2022.
Article in English | MEDLINE | ID: mdl-35891678

ABSTRACT

Background: The prevalence of diverticulitis has steadily increased during the past century. One possible complication of large bowel diverticulitis (LBD) is the concurrent development of a small bowel obstruction (SBO). The literature regarding these joint diagnoses is primarily limited to small case series from the 1950s. Consequently, no official recommendations or recent literature exists to guide decision making. Methods: This is a retrospective case-control study with 5:1 matching by demographics, comorbidities, and Hinchey classification of patients presenting with concomitant LBD and SBO and patients with LBD alone. The primary outcome assessed was the need for same admission surgical intervention. Results: Patients with concurrent LBD and SBO were more likely to require surgical intervention (OR 4.2, p<0.001) and more likely to receive an open operation than patients with only LBD (p<0.001). The length of stay (LOS) was longer for LBD with SBO (mean LOS +3.2 days, p=0.003). Discussion: Patients with concurrent LBD and SBO are more likely to fail non-operative management. Given this, along with their longer LOS and higher rate of open surgery, earlier surgical intervention may improve outcomes and reduce hospital LOS. Level of evidence: 4.

4.
Environ Toxicol Chem ; 34(2): 437-45, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25378272

ABSTRACT

The presence of endocrine-disrupting compounds (EDCs), particularly estrogenic compounds, in the environment has drawn public attention across the globe, yet a clear understanding of the extent and distribution of estrogenic EDCs in surface waters and their relationship to potential sources is lacking. The objective of the present study was to identify and examine the potential input of estrogenic EDC sources in North Carolina water bodies using a geographic information system (GIS) mapping and analysis approach. Existing data from state and federal agencies were used to create point and nonpoint source maps depicting the cumulative contribution of potential sources of estrogenic EDCs to North Carolina surface waters. Water was collected from 33 sites (12 associated with potential point sources, 12 associated with potential nonpoint sources, and 9 reference), to validate the predictive results of the GIS analysis. Estrogenicity (measured as 17ß-estradiol equivalence) ranged from 0.06 ng/L to 56.9 ng/L. However, the majority of sites (88%) had water 17ß-estradiol concentrations below 1 ng/L. Sites associated with point and nonpoint sources had significantly higher 17ß-estradiol levels than reference sites. The results suggested that water 17ß-estradiol was reflective of GIS predictions, confirming the relevance of landscape-level influences on water quality and validating the GIS approach to characterize such relationships.


Subject(s)
Endocrine Disruptors/analysis , Geographic Information Systems , Water Pollutants, Chemical/analysis , Estradiol/analysis , Estrogens/analysis , Geography , Least-Squares Analysis , Models, Theoretical , North Carolina
5.
Surg Oncol Clin N Am ; 21(1): 21-33, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22098829

ABSTRACT

Gastrointestinal stromal tumors (GISTs) are relatively rare mesenchymal tumors located within the submucosa of the GI tract. The defining characteristic of GISTs is the presence of the cell-surface antigen CD117 receptor tyrosine kinase, identified by immunohistochemistry. Currently the only cure for GIST is complete surgical resection. Imatinib has revolutionized the treatment of GISTs and has been used as adjuvant treatment after resection, and as treatment for locally advanced, recurrent, and metastatic GIST. Imatinib resistance has become a significant concern in the treatment of GISTs and other tyrosine kinase inhibitors that target different pathways are currently being studied.


Subject(s)
Gastrointestinal Stromal Tumors/therapy , Stomach Neoplasms/therapy , Antineoplastic Agents/therapeutic use , Benzamides , Chemotherapy, Adjuvant/methods , Drug Resistance, Neoplasm , Gastrointestinal Stromal Tumors/genetics , Gastrointestinal Stromal Tumors/pathology , Gastroscopy/methods , Humans , Imatinib Mesylate , Indoles/therapeutic use , Laparoscopy/methods , Mutation/genetics , Piperazines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-kit/genetics , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Radiotherapy, Adjuvant/methods , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Sunitinib
6.
Surg Oncol ; 21(2): 87-94, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21216590

ABSTRACT

Recent studies have lead to a renewed interest in cytoreductive surgery and intraperitoneal chemotherapy as a regional treatment modality for patients with peritoneal surface malignancies. There have been multiple phase III randomized trials that have shown a survival advantage with intraperitoneal chemotherapy in certain patients. More well designed phase III studies are needed to further define which groups of patients may benefit from cytoreductive surgery and intraperitoneal chemotherapy.


Subject(s)
Chemotherapy, Cancer, Regional Perfusion/methods , Peritoneal Neoplasms/drug therapy , Antineoplastic Agents/administration & dosage , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/surgery , Combined Modality Therapy/methods , Female , Humans , Hyperthermia, Induced/methods , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/surgery , Perioperative Care/methods , Peritoneal Neoplasms/surgery , Pseudomyxoma Peritonei/drug therapy , Pseudomyxoma Peritonei/surgery , Stomach Neoplasms/drug therapy , Stomach Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...